Cas9 Stable Cell Line - IPSC-DYR0100

The IPSC-DYR0100 cell line is a well-characterized human induced pluripotent stem cell line originally derived from dermal fibroblasts obtained from a healthy male donor. It has been widely used in the stem cell research community due to its robust pluripotency, normal karyotype, and reliable differentiation potential. The Cas9 Stable Cell Line - IPSC-DYR0100 is a derivative engineered to constitutively express the Streptococcus pyogenes Cas9 nuclease under a constitutive promoter, allowing researchers to bypass the need for transient Cas9 delivery through plasmids, mRNA, or protein. This stable expression ensures consistent and reproducible genome editing efficiencies across experiments, saving time and reducing variability associated with transfection-based methods. The line is maintained under standard feeder-free iPSC culture conditions and retains typical pluripotency markers, including Oct4, Sox2, and Nanog, as well as the ability to differentiate into all three germ layers.

From an application standpoint, the Cas9 Stable Cell Line - IPSC-DYR0100 serves as a versatile platform for high-throughput genetic screening, disease modeling, and functional genomics studies. Because Cas9 is already integrated into the genome, researchers can simply deliver single guide RNAs via lentiviral vectors or synthetic RNA to introduce targeted knockouts, point mutations, or reporter gene insertions without worrying about co-delivery of the Cas9 component. This is particularly valuable for generating isogenic disease models, where precise genetic modifications are introduced into a healthy iPSC background to study disease mechanisms or test drug responses. The stable Cas9 expression also makes the line suitable for pooled CRISPR screening applications, enabling genome-scale loss-of-function studies in a physiologically relevant human cell type. Additionally, the iPSC platform allows subsequent differentiation into various somatic cell types such as cardiomyocytes, neurons, and hepatocytes, meaning that gene edits introduced at the pluripotent stage can be studied in lineage-specific contexts. This combination of a well-validated parental iPSC line with stable Cas9 activity offers a streamlined workflow for laboratories focused on stem cell biology, gene therapy development, and precision medicine research.